14-day Premium Trial Subscription Try For FreeTry Free
$0.210
-0.0400 (-16.00%)
At Close: May 29, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session

 12:00am, Thursday, 16'th Apr 2020

Implied Volatility Surging for Ampio (AMPE) Stock Options

 02:41pm, Thursday, 02'nd Apr 2020
Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.

Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video

 01:11pm, Thursday, 02'nd Apr 2020

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

 01:00pm, Thursday, 02'nd Apr 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory co

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat ...

 12:00am, Thursday, 02'nd Apr 2020

Ampio Suspends Patient Enrollment In Phase 3 Study Of Ampion For Severe Osteoarthritis Of The Knee And Explores Other Options To Complete Trial As A Result Of Coronavirus Concerns

 11:03am, Tuesday, 24'th Mar 2020

Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

 11:00am, Tuesday, 24'th Mar 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clin

Ampio Says Is Preparing Expanded Access FDA Protocol To 'Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with' Coronavirus

 10:33am, Tuesday, 24'th Mar 2020

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

 10:30am, Tuesday, 24'th Mar 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory co

Ampio Suspends Patient Enrollment in its Phase ' Study of Ampion for Severe Osteoarthritis of ...

 12:00am, Tuesday, 24'th Mar 2020

Ampio Provides Corporate Update

 11:30am, Friday, 21'st Feb 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial titled "Evaluating the Efficac

Ampio Pharma 10-K Just Out; Includes Message About Co.'s Independent Registered Public Accounting Firm Having Expressed Substantial Doubt As To Co.'s Ability To Continue As A Going Concern

 11:21am, Friday, 21'st Feb 2020

Ampio Provides Corporate Update

 12:00am, Friday, 21'st Feb 2020

Here is What Hedge Funds Think About Ampio Pharmaceuticals, Inc. (AMPE)

 12:57am, Tuesday, 24'th Dec 2019
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exo

Roth Capital Initiates Coverage On Ampio Pharmaceuticals with Buy Rating, Announces $4 Price Target

 11:38am, Thursday, 19'th Dec 2019
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE